Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

Inclusion Criteria

• •1. Patients with Adenovirus infections post allogeneic HSCT, with primary immunodeficiencies or post solid organ transplant with:
• •* Increasing or persistent quantitative ADV RT-PCR DNA copies despite two weeks of appropriate anti-viral therapy and/or
• •* clinical symptoms attributed to adenovirus, including pneumonitis, hemorrhagic cystitis, colitis, hepatitis AND/OR
• •* Medical intolerance to anti-viral therapies including:
• •* grade 2 renal insufficiency secondary to cidofovir Consent: Written informed consent given (by patient or legal representative) prior to any study-related procedures.
• •Performance Status \> 30% (Lansky \< 16 yrs and Karnofsky \> 16 yrs) Age: 0.1 to 79 years
• •Females of childbearing potential with a negative urine pregnancy test
• •2. Donor Eligibility Related donor available with a T-cell response to the viral MACS® GMP PepTivator antigen(s) of adenovirus.
• •a. Third Party Related Allogeneic Donor: If original donor is not available or does not have a T-cell response: third party allogeneic donor (family donor \> 1 HLA A, B, DR match to recipient) with a T-cell response at least to the viral MACS® GMP PepTivator antigen(s) of adenovirus.
• •AND Allogeneic donor disease screening is complete similar to hematopoietic stem cell donors (Appendix 1).
• •AND Obtained informed consents by donor or donor legally authorized representative prior to donor collection.